METAGENOMI THERAPEUTICS INC (MGX) Fundamental Analysis & Valuation

NASDAQ:MGX • US59102M1045

Current stock price

1.32 USD
-0.07 (-5.04%)
At close:
1.32 USD
0 (0%)
After Hours:

This MGX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. MGX Profitability Analysis

1.1 Basic Checks

  • In the past year MGX has reported negative net income.
  • In the past year MGX has reported a negative cash flow from operations.
  • In the past 5 years MGX always reported negative net income.
  • The reported operating cash flow has been mixed in the past 5 years: MGX reported negative operating cash flow in multiple years.
MGX Yearly Net Income VS EBIT VS OCF VS FCFMGX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 2025 0 -50M -100M

1.2 Ratios

  • MGX has a Return On Assets of -39.74%. This is comparable to the rest of the industry: MGX outperforms 57.06% of its industry peers.
  • MGX's Return On Equity of -55.40% is fine compared to the rest of the industry. MGX outperforms 61.12% of its industry peers.
Industry RankSector Rank
ROA -39.74%
ROE -55.4%
ROIC N/A
ROA(3y)-27.5%
ROA(5y)-21.62%
ROE(3y)-40.12%
ROE(5y)-37.04%
ROIC(3y)N/A
ROIC(5y)N/A
MGX Yearly ROA, ROE, ROICMGX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 2025 -10 -20 -30 -40 -50

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for MGX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MGX Yearly Profit, Operating, Gross MarginsMGX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 2025 -2K -4K -6K -8K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. MGX Health Analysis

2.1 Basic Checks

  • MGX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, MGX has more shares outstanding
  • There is no outstanding debt for MGX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
MGX Yearly Shares OutstandingMGX Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 2025 10M 20M 30M
MGX Yearly Total Debt VS Total AssetsMGX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 2025 100M 200M 300M 400M

2.2 Solvency

  • Based on the Altman-Z score of -2.04, we must say that MGX is in the distress zone and has some risk of bankruptcy.
  • MGX has a Altman-Z score of -2.04. This is comparable to the rest of the industry: MGX outperforms 49.71% of its industry peers.
  • There is no outstanding debt for MGX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.04
ROIC/WACCN/A
WACC9.37%
MGX Yearly LT Debt VS Equity VS FCFMGX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 2025 0 100M -100M 200M

2.3 Liquidity

  • A Current Ratio of 7.22 indicates that MGX has no problem at all paying its short term obligations.
  • With a decent Current ratio value of 7.22, MGX is doing good in the industry, outperforming 67.89% of the companies in the same industry.
  • A Quick Ratio of 7.22 indicates that MGX has no problem at all paying its short term obligations.
  • With a decent Quick ratio value of 7.22, MGX is doing good in the industry, outperforming 68.28% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.22
Quick Ratio 7.22
MGX Yearly Current Assets VS Current LiabilitesMGX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 2025 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. MGX Growth Analysis

3.1 Past

  • MGX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 9.54%, which is quite good.
  • The Revenue for MGX has decreased by -51.79% in the past year. This is quite bad
  • The Revenue has been growing by 13.59% on average over the past years. This is quite good.
EPS 1Y (TTM)9.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%4.76%
Revenue 1Y (TTM)-51.79%
Revenue growth 3Y13.59%
Revenue growth 5YN/A
Sales Q2Q%-59.32%

3.2 Future

  • The Earnings Per Share is expected to grow by 7.21% on average over the next years.
  • Based on estimates for the next years, MGX will show a decrease in Revenue. The Revenue will decrease by -4.26% on average per year.
EPS Next Y22.46%
EPS Next 2Y14.75%
EPS Next 3Y14.29%
EPS Next 5Y7.21%
Revenue Next Year-15.35%
Revenue Next 2Y-9.76%
Revenue Next 3Y-10.58%
Revenue Next 5Y-4.26%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
MGX Yearly Revenue VS EstimatesMGX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M
MGX Yearly EPS VS EstimatesMGX Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 -4

More info and screens

Find the best growth stocksShow best growing peers

0

4. MGX Valuation Analysis

4.1 Price/Earnings Ratio

  • MGX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MGX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MGX Price Earnings VS Forward Price EarningsMGX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MGX Per share dataMGX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

  • MGX's earnings are expected to grow with 14.29% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.75%
EPS Next 3Y14.29%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MGX Dividend Analysis

5.1 Amount

  • MGX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MGX Fundamentals: All Metrics, Ratios and Statistics

METAGENOMI THERAPEUTICS INC

NASDAQ:MGX (3/27/2026, 8:00:01 PM)

After market: 1.32 0 (0%)

1.32

-0.07 (-5.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-05
Earnings (Next)05-08
Inst Owners20.17%
Inst Owner Change14.41%
Ins Owners9.56%
Ins Owner Change4.47%
Market Cap49.66M
Revenue(TTM)25.21M
Net Income(TTM)-87.87M
Analysts80
Price Target9.52 (621.21%)
Short Float %7.2%
Short Ratio7.06
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)4.31%
Min EPS beat(2)1.87%
Max EPS beat(2)6.75%
EPS beat(4)3
Avg EPS beat(4)1.51%
Min EPS beat(4)-16.48%
Max EPS beat(4)13.9%
EPS beat(8)6
Avg EPS beat(8)7.76%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-13.37%
Min Revenue beat(2)-42.59%
Max Revenue beat(2)15.86%
Revenue beat(4)2
Avg Revenue beat(4)-16.55%
Min Revenue beat(4)-48.67%
Max Revenue beat(4)15.86%
Revenue beat(8)6
Avg Revenue beat(8)11.53%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)7.6%
EPS NQ rev (3m)7.6%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)31.33%
Revenue NQ rev (3m)31.33%
Revenue NY rev (1m)7.64%
Revenue NY rev (3m)7.64%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.97
P/FCF N/A
P/OCF N/A
P/B 0.31
P/tB 0.31
EV/EBITDA N/A
EPS(TTM)-2.37
EYN/A
EPS(NY)-1.84
Fwd EYN/A
FCF(TTM)-2.38
FCFYN/A
OCF(TTM)-2.36
OCFYN/A
SpS0.67
BVpS4.22
TBVpS4.22
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -39.74%
ROE -55.4%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-27.5%
ROA(5y)-21.62%
ROE(3y)-40.12%
ROE(5y)-37.04%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.11
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10.8%
Cap/Sales 2.28%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.22
Quick Ratio 7.22
Altman-Z -2.04
F-Score2
WACC9.37%
ROIC/WACCN/A
Cap/Depr(3y)100.56%
Cap/Depr(5y)371.66%
Cap/Sales(3y)10.05%
Cap/Sales(5y)261.21%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)9.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%4.76%
EPS Next Y22.46%
EPS Next 2Y14.75%
EPS Next 3Y14.29%
EPS Next 5Y7.21%
Revenue 1Y (TTM)-51.79%
Revenue growth 3Y13.59%
Revenue growth 5YN/A
Sales Q2Q%-59.32%
Revenue Next Year-15.35%
Revenue Next 2Y-9.76%
Revenue Next 3Y-10.58%
Revenue Next 5Y-4.26%
EBIT growth 1Y-8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-13.39%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y20.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y18.5%
OCF growth 3YN/A
OCF growth 5YN/A

METAGENOMI THERAPEUTICS INC / MGX Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for METAGENOMI THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to MGX.


What is the valuation status of METAGENOMI THERAPEUTICS INC (MGX) stock?

ChartMill assigns a valuation rating of 0 / 10 to METAGENOMI THERAPEUTICS INC (MGX). This can be considered as Overvalued.


What is the profitability of MGX stock?

METAGENOMI THERAPEUTICS INC (MGX) has a profitability rating of 1 / 10.


Can you provide the financial health for MGX stock?

The financial health rating of METAGENOMI THERAPEUTICS INC (MGX) is 7 / 10.